IP Library Granted Patent US 9,156,892
Granted Patent B2
US 9,156,892 · App. 13/488,662 · Granted Oct 13, 2015

Mutated immunoglobulin-binding protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,156,892
App. No.
13/488,662
Granted
Oct 13, 2015
Kind
B2
Abstract

The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

Claims (12)

1. An immunoglobulin-binding protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), wherein at least the asparagine residue at position 6 or 11 of a parental immunoglobulin-binding protein defined by SEQ ID NO. 1 or 2, has been mutated to an amino acid other than glutamine, which mutation has conferred an increased chemical stability at alkaline pH-values compared to the parental molecule.

2. The protein of claim 1 , which is an Fc fragment-binding protein.

3. The protein of claim 1 , wherein the mutation(s) are selected from the group consisting of N6A; N11S; N11S and N23T; and N6A and N23T; and wherein the parental molecule comprises the sequence defined by SEQ ID NO. 2.

4. The protein of claim 1 , wherein the asparagine residue in position 23 has been mutated, preferably to a threonine residue.

5. The protein of claim 1 , wherein one or two asparagine residues are mutated.

6. The protein of claim 1 , further comprising an N23T mutation.

7. A multimer comprised of mutated protein units of claim 1 , which comprises two or more repetitive units.

8. The multimer of claim 7 , which further comprises a C-terminal cysteine.

9. The multimer of claim 7 , wherein the protein units are linked by elements including up to about 15 amino acids.

10. The multimer of claim 7 , further comprising one or more of the E, D, A, B, and C domains of Staphylococcus protein A.

11. The multimer of claim 7 , which is a tetramer.

12. The multimer of claim 11 , wherein each protein unit is the protein defined by SEQ ID NO. 2 and includes the mutation N23T.

Assignments (4)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2012
From: HOBER, SOPHIA
To: AMERSHAM BIOSCIENCES AB
Reel/Frame 028318/0523 →
CHANGE OF NAME Recorded Jun 5, 2012
From: AMERSHAM BIOSCIENCES AB
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 028324/0233 →